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VIRAL INFECTIONS IN PREGNANCY
The importance of protecting pregnant women from infection as well as
from possible harmful effects of various medications and other noxious
agents has received increasing attention in recent years. Much of the work
related to viral diseases has been directed toward (1) identifying the agents
that might be associated with fetal wastage and congenital malformations;
(2) determining the risk to the fetus when women are infected during
pregnancy; (3) elucidating the pathogenesis of fetal infections; and (4)
considering means of control by vaccination or other measures when
feasible.
There has been little statistically valid information on the incidence of
viral infections in pregnancy. In a six year prospective survey of some
30,000 pregnant women, investigators in the Collaborative Perinatal Re-
search Study attempted to assess the actual frequency of viral infection in
this group.' Clinical information on the occurrence of various types of ill-
ness was collected and paired serum specimens (taken at the first prenatal
visit and at the time of delivery) were examined for the development of
antibodies against a number of common viruses. Some 1,600 of the women
reported illness presumed viral, excluding episodes of the common cold.
Most were acute influenza-like respiratory infections, herpes simplex, and
a variety of nonspecific syndromes. The incidence of specific diseases was
low. Serologic tests confirmed the clinical diagnoses and gave the following
minimum attack rates per 10,000: 10 for mumps, 8 for rubella, 5 for vari-
cella zoster, and 0.6 for measles. Inapparent infections were also docu-
mented by serologic means. In one group of 2,000 women, there were sig-
nificant complement fixing antibody rises to cytomegalovirus in 3 percent;
to influenza B in 4.4 percent; and to adenoviruses in 1.4 percent.
Unfortunately it was not possible in this study to document the influence
of infection in the early months of pregnancy since women usually are not
seen for prenatal care until late in the first trimester. Nevertheless the
above results provide some indication of the size of the problem.
Infection during pregnancy can be viewed in terms of its significance for
the mother-i.e. increased morbidity and mortality, or in relation to its
effects on the fetus. The range includes no involvement, or fetal infection
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that may be apparent or inapparent, acute (with recovery or death), or
chronic (with or without malformations.) The relationship between ma-
ternal and fetal infection is a complex one because of the presence of the
placenta. In addition, the endocrinologic features peculiar to the pregnant
state exert an effect on the maternal response, and presumably account for
the increased incidence and severity of certain diseases in pregnant women.
The role of the placenta is a changing one during the course of gestation.
After the first 11-12 weeks it acts as a barrier to fetal infection, while it
does not do so earlier. The significance of this point is illustrated in the
difference between the risk to the fetus when maternal rubella occurs in the
first trimester as compared to the second or third. Furthermore, pathologic
changes occur in the placenta in some virus infections, but not in others.
Rubella, herpes simplex, varicella, smallpox, and vaccinia all result in
lesions of the villous tissue, which include necrosis, acute inflammation,
granulomatous changes, and monoculear infiltrates. In contrast, other
documented virus infections of the fetus (poliomyelitis, Coxsackie B) leave
no discernible trace in the placenta. It seems clear that some viruses do not
affect the placenta; others may infect the placenta but extend no further,
while still others spread from the placenta to the fetus and may cause
severe damage.
EFFECTS OF VIRAL INFECTIONS IN RELATION TO MATERNAL
AND FETAL RESPONSE (Table 1)
The common upper respiratory illnesses-"URI," coryza, pharyngitis,
etc.-behave similarly in pregnant and nonpregnant individuals and they
appear to have no influence on the fetus. The same is true, by and large,
of influenza. However, in certain epidemics such as the 1957 one caused by
the Asian (A2) strain, increased severity and mortality were noted,' par-
ticularly when the disease occurred late in pregnancy. In the course of that
same outbreak prospective studies were carried out by several groups of
investigators to determine whether influenza virus infection resulted in
any teratogenic effects on the fetus. The results were conflicting. An investi-
gation of 75 women with influenza and of matched controls, carried out by
Wilson, et al.,' failed to reveal any malformations in the offspring, while a
similar investigation in Dublin noted an increase in anencephaly in the
babies.' Since laboratory tests were not used to confirm the diagnosis of
influenza in the latter study, the data are not impressive, and it seems un-
likely that maternal influenza is associated with malformations.! However,
there is some suggestion in other data that when the disease occurs early
in pregnancy, there is increased fetal wastage.
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TABLE 1. VIRAL INFECTIONS IN PREGNANCY
Viruses
Agents causing common
respiratory illnesses
Influenza
Mumps
Poliomyelitis
Coxsackie B
Echo-9
Hepatitis
Measles
Smallpox
Vaccinia
Varicella-zoster
Herpes simplex
Cytomegaloviruses
Rubella
Effects-Maternal and/or fetal
None
Usually none; increased maternal morbidity and mortality
in certain epidemics
Fetal death; ? fetal abnormalities
Increased maternal morbidity and mortality; congenital
paralytic poliomyelitis
Neonatal myocarditis and encephalitis
None
Increased severity of maternal infection; fetal death;
neonatal hepatitis
Fetal death
Fetal death; congenital smallpox
Congenital generalized vaccinia
Congenital chickenpox; disseminated neonatal infection;
rarely, congenital anomalies
Disseminated neonatal infection
Congenital anomalies: microcephaly, chorioretinitis,
hepatosplenomegaly, jaundice, deafness, mental
retardation
Increased abortion and stillbirths
Congenital anomalies: cataracts, hearing loss, heart
lesions, thrombocytopenic purpura, microcephaly,
psychomotor retardation, etc.
Mumps has been the subject of several types of studies in recent years.
In 1963 a report appeared indicating that a high proportion of infants with
endocardial fibroelastosis (EFE) give positive skin reactions of delayed
hypersensitivity to mumps antigen.' This was quickly followed by several
attempts to determine if intrauterine mumps infection was indeed associ-
ated with EFE. Critical study of the matter has produced no solid evidence
of such an association :' immune tolerance to mumps virus is not present in
children with EFE, and the virus has never been detected in infants with
this anomaly. Such children do not have circulating mumps antibody and
in fact develop the disease when subsequently exposed. Finally, the mumps
skin test, on which the evidence for an association primarily rests, is no-
toriously unreliable even when proper control antigens are employed.
If mumps does cause any malformation, the experiments of Johnson!
would suggest that it might be congenital stenosis of the aqueduct of Syl-
vius. When mumps virus was injected intracerebrally into suckling hams-
ters there was no demonstrable acute reaction. However, if the animals
were held for a longer period they developed hydrocephalus which was due
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to stenosis of the acqueduct, secondary to inapparent infection of the epen-
dymal cells. The animals had acquired mumps antibody but virus was no
longer present in any of their tissues. Whether a parallel phenomenon
might occur in man is unknown.
Mumps infection in pregnancy has also been examined by Siegel, et al.'
in a prospective study to identify infections associated with fetal death in
the first trimester. Compared to findings in matched controls, mumps was
found to be associated with a significant increase in incidence of spontaneous
abortion when it occurred in each of the first three months of pregnancy
(mumps, 27.3% vs. controls, 13.0%). Perinatal mortality was similar in
infants of cases and controls.
Poliomyelitis is no longer a threat in this part of the world, but not so
long ago there was an increasing incidence in young adults, and it was
apparent then that the disease was more frequent in pregnant women than
in controls in the same age group,'0 and that the severity and mortality were
increased. Infection in the first trimester resulted in a high fetal mortality;
when it occurred near term or during delivery it was associated occasionally
with paralytic disease in the neonatal period.'
A somewhat similar situation prevails with respect to Coxsackie B virus
infection. As with polio- and other enteroviruses the circulation of these
agents is primarily among young children, but when a susceptible mother
becomes infected in the prepartum period, usually with mild clinical con-
sequences, perinatal infection of the fetus may result in a severe, highly
fatal encephalomyocarditis.'2 Milder degrees of involvement also occur, and
in fact, the baby may have a totally inapparent infection.'-1
Recently two types of evidence have been presented which suggest that
Coxsackie B virus infections acquired in utero or during birth may be as-
sociated with congenital heart disease. Burch and his colleagues, using im-
munofluorescence techniques, claim to have demonstrated Coxsackie B virus
antigen in the myocardium of stillbirths and infants dying in the neonatal
period in whom no heart disease was suspected.l' These results have not yet
been confirmed and their significance is at present unknown. Using another
approach, Brown, et al., in a prospective serologic study of pregnant wom-
en, found that there were more antibody conversions (largely asympto-
matic) against Coxsackie B viruses among mothers who delivered infants
with congenital heart disease than among matched controls.' The numbers
involved in both groups were too small, however, to make firm conclusions
as to an association.
Few other studies have focussed on possible teratogenic effects of en-
terovirus infection early in pregnancy, but one well-designed one was car-
ried out in Milwaukee during the extensive 1957 echo virus 9 epidemic."
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Infected women were followed to term, and there was no evidence of any
increase in abnormalities in their babies as compared to controls. Similar
observations have been made with respect to poliomyelitis.'
Hepatitis, like poliomyelitis, seems to be more severe in pregnant women,
particularly near term, and infants infected in utero have been born with
the clinical disease.'m There is also evidence of increased fetal death when
the infection occurs in the first trimester.'
Measles has also been examined for its effect on the fetus during early
pregnancy, but the cases were too few to allow conclusions to be drawn.'
Since the disease is so rare in the childbearing age in urban communities, it
is necessary to look at outbreaks in so-called virgin soil populations to find
adequate numbers for study. The epidemics in Greenland" support the con-
clusion that measles early in pregnancy results in a high abortion rate,
which may reach 33 percent. Although congenital anomalies have oc-
casionally been observed, the data are insufficient to suggest that their oc-
currence exceeds that in controls.
Congenital smallpox has long been recognized as a consequence of in
utero infection.' Abortion is common when the disease occurs early in
pregnancy, and the increased mortality reflects the unusual severity of
smallpox in pregnant women.' Vaccinia is not without hazard since it is
a live virus vaccine; transmission to the fetus with congenital infection has
occurred primarily in women who had never been vaccinated before."t
Three members of the herpes group of viruses-varicella-zoster, herpes
simplex, and cytonmegaloviruses-have been implicated in fetal and neonatal
disease. Severe, even fatal, maternal infection, abortion, and fetal abnormali-
ties have been reported as complications of varicella-zoster infection in
pregnancy; their true incidence is unknown but they must be exceedingly
uncommon. The spectrum of clinical response in congenital chickenpox
varies from mild, almost inapparent, with few pox, to a severe disseminated
disease with extensive visceral involvement.' The latter is fortunately rare
and the usual course in the infant is mild and uncomplicated. Depending on
when the maternal disease occurs in relation to delivery, the disease in the
newborn may be present at birth, or the lesions may not appear for as long
as three weeks or more. Two recent reports from New York City"
showed that among a total of 29 cases of varicella-zoster infection in preg-
nancy, 26 of the women were from Puerto Rico, one from Cuba, and only
two from the United States. In one of the studies, 7 of 17 infants developed
varicella in the neonatal period, and all had benign courses.' The other 10
infants gave no evidence of infection. Since serologic tests are difficult and
relatively insensitive, the possibility that the normal children experienced
inapparent intrauterine infection was not investigated.
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Herpes simplex virus is a well recognized cause of a severe neonatal
disseminated disease of which more than 60 cases have been reported.'
However, there is no evidence that herpes virus causes stillbirth or abor-
tion. The infection may be acquired in utero or, more commonly, during
passage through the birth canal. When it occurs in utero, it is probably as-
sociated with transplacental passage during a primary infection in a young
mother who has escaped experience with the virus in childhood. Herpes
genital tract; it has been isolated in the absence of overt lesions from the
vagina of a mother whose baby died of disseminated infection.' Several re-
cent reports implicate herpes virus in infants with congenital anomalies of
the central nervous system (microcephaly, intracranial calcifications, retinal
dysplasia, and microphthalmus). From the vesicular skin lesions in one
of the cases a genital strain of herpes virus (type 2) was recovered. The
infant's mother had had a recognized vaginal infection in early pregnancy.'
Cytomegaloziruses, also members of the herpes group, were first isolated
in 1956-57 almost simultaneously by several groups of investigators. Wel-
ler, et al. were the first to establish the clinical significance of the congenital
infection when they recovered the agent from a newborn infant who had
the typical clinical picture of congenital toxoplasmosis." Subsequently a
great deal has been learned about cytomegaloviruses, and it is now apparent
that infection of the mother during pregnancy commonly results in infection
of the infant, but disease in the infant is far less common. Hanshaw3' has
stressed the frequent association of microcephaly with serologic evidence of
CMV infection in young children; other characteristic features, present at
birth, are hepato-splenomegaly, jaundice, petechiae, chorioretinitis, and
motor disability. To determine the incidence of apparent and inapparent
congenital infection, Starr, et al.' conducted a study at the Cleveland
Metropolitan Hospital in which urine samples from 2,147, one day old in-
fants were tested for CMV. Twenty-seven infections were identified, giv-
ing a rate of 1.3%o, or 1 in 83 infants, a figure close to that reported by
others. Infection was demonstrated in the urine of 60 percent of the mothers
(all asymptomatic) of infected infants. Two thirds of them were primiparas,
and they were young (average age, 19 years with 13 in the 15-19 age
group). Although infected infants were on the small side, only one of the
27 had overt manifestations of CMV disease. The study suggests that CMV
infection is not uncommon but that severe sequellae are infrequent in in-
fected infants.
Of all of the viral infections, rubella is the most important cause of fetal
wastage and congenital malformation. When maternal infection occurs in
the first 12 weeks of gestation, the estimated risk of fetal malformations
detectable in the neonatal period is approximately 20 percent. This figure
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is based on well-controlled prospective studies, carried out in Great Britain,
Sweden, and the United States." When children are followed over a
period of years, the recognition of impaired hearing and other anomalies
increases the rate to approximately 35 percent.'M There is also evidence that
preconception rubella can result in fetal defect.' Maternal infection in the
second trimester also carries some hazard, although much less than when
it occurs in the first trimester.9TMT2 7
Response of the fetus to rubella virus covers a wide range. The infection
may cause no apparent damage, or it may result in single, mild to multiple,
severe anomalies; spontaneous abortion and stillbirths occur at twice the
normal rate. The most characteristic abnormalities are those of the "rubella
triad," consisting of heart lesions (chiefly patent ductus arteriosus), cata-
racts, and deafness. Following the 1964 epidemic in the United States,
some 20,000-30,000 infants were born with the rubella syndrome, and vir-
tually every organ and tissue has been reported to be involved. In addition
to the classic syndrome, petechiae, thrombocytopenic purpura, hepato-
splenomegaly, transient bone lesions, chronic meningitis, hepatitis, and a
variety of other anomalies were seen.8
Like cytomegaloviruses, rubella induces a chronic persistent infection
in the fetus, and at birth infants are still shedding virus from the throat.
The immunologic problem is not clearly understood, but immune tolerance
is not the explanation since the infants have specific endogenously produced
antibody. It seems probable that infected clones of cells continue to produce
virus, but their life span is somewhat shortened. Only when all such clones
have disappeared does the production of virus cease. By six months of age
the number of infants from whom virus can still be recovered falls to 20-
30%, and very few continue to have detectable virus in the throat after one
year.T'- During this period of continued virus shedding, the infants are a
source of infection to susceptibles who come in contact with them.
SCREENING OF NEWBORNS FOR THE DETECTION OF
INTRAUTERINE INFECTION
Recent developments in immunology have changed older concepts about
the inability of the human fetus to respond to antigenic stimuli. At birth
the normal infant possesses only yG immunoglobulin which is transferred
across the placenta from the mother. Since 'yM and yA do not pass the
placental barrier, their presence indicates endogenous production in fetal
tissues. It is now apparent that synthesis of yM immunoglobulin can occur
as early as the sixteenth week of gestation. In contrast to the course of
response to infection in post-natal life in which the yM fraction appears
first and is rapidly replaced by -yG activity, in the fetus yM commonly per-
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sists for months and is usually present at birth. On the basis of this obser-
vation, cord bloods of apparently normal infants and those suspected of
having experienced intrauterine infection have been examined for the
presence of yM immunoglobulins.' Elevated levels have been found with
some regularity in newborns known to have been infected in utero with a
wide variety of infectious agents. Some of these infants have had obvious
clinical evidence of congenital disease such as rubella, syphillis, cytomegalo-
virus disease, etc.; in others the infections have been inapparent, particular-
ly when such agents as CMV and toxoplasma were involved. Although the
presence of elevated yM levels at birth indicates intrauterine infection, such
infection can occur without abnormal yM levels. Abnormally high levels
constitute a nonspecific finding and it is necessary to use other methods to
demonstrate the nature of the infection. Immunofluorescence methods for
detection of specific antibody are now coming into use; they should prove
a rapid means of determining the etiology of intrauterine infections.
PREVENTION OF INFECTION IN PREGNANCY
To begin with the most important infection, rubella: almost as soon
as the virus was isolated in 1962, investigators began trying to de-
velop vaccines, both killed and attenuated live virus types. The agent was
found to propagate well in a variety of primary cell cultures and in certain
continuous cell lines. At first there was considerable effort to produce an
inactivated vaccine, similar to the Salk-type poliovirus vaccine. The results
proved uniformly disappointing, since the various forms of inactivation
caused great loss of antigenic potency. Another approach, viz. attenuation
of the virus by passage in tissue culture, has had considerably more success,
TABLE 2. RUBELLA VACCINES THAT HAVE UNDERGONE FIELD TRIAL
Tissue culture cell
Virus strain* in which prepared
HPV,n" Green monkey kidney
HPV7T'6 Duck embryo
HPV77 DKu" Dog kidney
Benoit' Duck embryo
Cendehill'8 Rabbit kidney
RA 27/3'7 WIs8 (human diploid)
* Superscripts refer to references.
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and in fact there are at present some five vaccines that have had extensive
field trial (Table 2). The first to be licensed anywhere was the Cendehill
straine8 which was approved in Switzerland in the spring of 1969. An
HPV77 derived vaccine was licensed in the United States in June, 1969.
Parkman and Meyer" were the first to develop a successful vaccine strain,
designating it HPV77, which stands for "high passage virus" after 77
serial transfers in green monkey kidney (GMK) tissue cultures. This re-
sulted in alteration in certain in vitro characteristics, and when tested in
monkeys the vaccine virus was shown to differ from wild strains in that it
no longer resulted in viremia or shedding from the throat, and failed to
infect close contacts. The next step was to test it cautiously in susceptible
volunteers. It was found that all developed antibody responses without any
illness, and there was no contact spread under conditions of rigorous test.
None of the vaccinees had detectable viremia but a significant proportion did
shed virus from the throat, in small amounts, and for brief periods. Since
primary monkey kidney is not an acceptable substrate for a vaccine that
must be injected, efforts were made to adapt HPV77 to other culture sys-
tems. Dr. Hilleman and his group succeeded in getting it to grow in duck
embryo tissue culture (HPV77 D5)," and Musser, in canine kidney cells
(HPV77 DK12).' These vaccines, the Cendehill,' and RA 27/3 of Plotkin4
which has been grown only in human diploid cells (Table 2), have been
tested in a total of more than 40,000 individuals. They all behave similarly
in that they induce antibodies in >95 percent of vaccinees; the HPV77
derivates have been shown to confer protection against clinical rubella on
exposure in a natural epidemic.' There is no spread to contacts, and in
children virtually no clinical reactions of any kind follow vaccination. It was
therefore a surprise when the vaccines were tried in adult women to dis-
cover that, as with the natural disease, arthralgia and arthritis were com-
plications in a significant proportion (20-30%o) of those receiving HPV77
derivatives," and to a lesser extent in those given Cendehill," or RA 27/3.'
Because all rubella vaccines contain live virus, they are contraindicated
in pregnancy. This is particularly true since there is now evidence from
trials in women scheduled for therapeutic abortion that the attenuated virus
can infect the placenta, and probably the fetus.' In the United States, the
Public Health Service and the Academy of Pediatrics Committee on the
Control of Infectious Diseases have therefore recommended that the vac-
cine be used primarily for school-aged children, in whom the greatest cir-
culation of virus occurs and who constitute the main source of infection for
adults."' In the continental United States, by age 15 to 19 at least 80 per-
cent of the population is immune from previous infection, either apparent
or inapparent. If feasible, a serologic test for immunity should be made to
107
HORSTMANNYALE JOURNAL OF BIOLOGY AND MEDICINE
identify susceptible adolescents and women. Vaccine should then be given to
them only if there is virtually no chance of pregnancy in the ensuing two
months.
There are still unanswered questions concerning rubella vaccine. Anti-
body levels have been maintained satisfactorily for the three years for which
there is now data,' but their long-range persistence is not yet known. There
is evidence that reinfection at the subclinical level occurs in vaccinees ex-
posed to natural rubella infection."M' Whether this poses a hazard to the
fetus is unknown. Reinfection happens also after natural infection, although
the meager evidence available suggests that it is much less frequent than
following artificial immunization. There are quantitative and probably
qualitative differences between the antibody responses to vaccine and to
natural infection. Hemagglutination-inhibition (HI) titers following vac-
cination are 4 to 8-fold lower; some vaccinees fail to develop complement
fixing antibodies, and particularly sensitive antigens are necessary to detect
post-vaccinal immune responses by the fluorescence (FA) test.' Further
investigations are necessary to determine the significance of these observa-
tions. Thus while the new rubella vaccines are something of a triumph,
there is still a good deal to be learned about their long term efficacy.
Against cytomegaloviruses there are no specific measures available. In-
apparent infection is relatively common in young children, and excretion of
the virus in the urine continues over many months. Persons with altered
immune mechanisms such as leukemics, patients who have undergone organ
transplant, and those on immunosuppressive therapy are particularly prone
to develop CMV infections. There are few data on the actual risks involved,
but it would seem wise to protect pregnant women from exposure to known
or potentially infected individuals, as far as possible.
Nor are there specific measures to prevent infection with herpes simplex
vieus. If a pregnant woman at term is known to be infected and to be har-
boring the virus in the genital tract, consideration should probably be given
to performing a Caesarian section, although this will not always prevent
transmission of the agent to the infant.
Vaccines are available for influenza, mumps, and measles, all three being
diseases that rarely cause problems during pregnancy. If an epidemic of
influenza is anticipated, immunization of pregnant women is desirable, par-
ticularly in those near term. The vaccine consists of killed virus and is ap-
proximately 70 percent effective. The currently available purified prepara-
tions cause little if any reaction.
Measlese and mumpses vaccines are live, attenuated virus preparations,
and therefore should not be given during pregnancy. Extremely few women
of child bearing age are susceptible to measles, and, except in isolated com-
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munities, it is not a problem in this age group. Immunity to mumps is
somewhat less prevalent, and immunization is indicated for girls as well as
boys approaching puberty who give no history of the disease.
Smallpox vaccine contains living vaccinia virus and primary vaccination
is contraindicated in pregnancy. Even the very slight risk from re-vaccina-
tion is enough to warrant withholding vaccination of pregnant women un-
less they are going to areas of high prevalence of smallpox and the risk of
exposure is great.
Pregnant women intimately exposed to hepatitis in the family setting
should be given immune globulin (human) in the dosage of 0.02 ml. per
lb. This amount, if administered soon after contact, modifies the infection
and prevents the disease.
Poliomyelitis has been virtually eliminated in the United States, and if
immunization of oncoming generations with oral poliovirus vaccine (OPV)
is continued, this happy situation will be maintained. Because of the negli-
gible chance of exposure, vaccination of unimmunized adults (including
pregnant women) is recommended only in the event of travel to endemic
or epidemic areas. For primary immunization two doses of trivalent OPV
at 6-8 week intervals followed by a third 6 to 12 months later are recom-
mended.
The protection of pregnant women from exposure to potentially hazard-
ous infections, an approach that sounds rational, is often impractical be-
cause the index infection so often is inapparent in diseases such as rubella,
cytomegalovirus, and others. In the hospital setting, however, it would
seem wise to screen nurses assigned to the newborn service for antibodies
to rubella, CMV, and in due course to other agents that are found to be
teratogenic. By this means susceptibles could be either assigned elsewhere,
or immunized if and when appropriate vaccines are available.
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